• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

保守抗原表位在开发通用 SARS 样冠状病毒疫苗中的潜力。

Potential of conserved antigenic sites in development of universal SARS-like coronavirus vaccines.

机构信息

State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences, School of Public Health, Xiamen University, Xiamen, China.

Department of Pulmonary Medicine, The First Affiliated Hospital of Xiamen University, Xiamen, China.

出版信息

Front Immunol. 2022 Sep 20;13:952650. doi: 10.3389/fimmu.2022.952650. eCollection 2022.

DOI:10.3389/fimmu.2022.952650
PMID:36203593
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9530325/
Abstract

Given pandemic risks of zoonotic SARS-CoV-2 variants and other SARS-like coronaviruses in the future, it is valuable to perform studies on conserved antigenic sites to design universal SARS-like coronavirus vaccines. By using antibodies obtained from convalescent COVID-19 patients, we succeeded in functional comparison of conserved antigenic sites at multiple aspects with each other, and even with SARS-CoV-2 unique antigenic sites, which promotes the cognition of process of humoral immune response to the conserved antigenic sites. The conserved antigenic sites between SARS-CoV-2 and SARS-CoV can effectively induce affinity maturation of cross-binding antibodies, finally resulting in broadly neutralizing antibodies against multiple variants of concern, which provides an important basis for universal vaccine design, however they are subdominant, putatively due to their lower accessibility relative to SARS-CoV-2 unique antigenic sites. Furthermore, we preliminarily design RBDs to improve the immunogenicity of these conserved antigenic sites. Our study focusing on conserved antigenic sites provides insights for promoting the development of universal SARS-like coronavirus vaccines, thereby enhancing our pandemic preparedness.

摘要

鉴于未来动物源性 SARS-CoV-2 变异株和其他 SARS 样冠状病毒的大流行风险，研究保守抗原表位以设计通用 SARS 样冠状病毒疫苗具有重要价值。通过使用从 COVID-19 恢复期患者获得的抗体，我们成功地从多个方面对保守抗原表位进行了功能比较，甚至与 SARS-CoV-2 独特的抗原表位进行了比较，这促进了对保守抗原表位体液免疫反应过程的认识。SARS-CoV-2 和 SARS-CoV 之间的保守抗原表位可以有效地诱导交叉结合抗体的亲和力成熟，最终产生针对多种关注变异株的广泛中和抗体，这为通用疫苗设计提供了重要依据，然而，这些保守抗原表位是次要的，推测是由于它们的可及性相对 SARS-CoV-2 独特的抗原表位较低。此外，我们初步设计了 RBD 来提高这些保守抗原表位的免疫原性。我们对保守抗原表位的研究为促进通用 SARS 样冠状病毒疫苗的发展提供了思路，从而增强了我们的大流行准备。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4b2/9530325/fc12e75e6680/fimmu-13-952650-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4b2/9530325/3af0e44612e7/fimmu-13-952650-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4b2/9530325/34cab0baa2d9/fimmu-13-952650-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4b2/9530325/f0f5a7a9a4bb/fimmu-13-952650-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4b2/9530325/02e763ece853/fimmu-13-952650-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4b2/9530325/fc12e75e6680/fimmu-13-952650-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4b2/9530325/3af0e44612e7/fimmu-13-952650-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4b2/9530325/34cab0baa2d9/fimmu-13-952650-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4b2/9530325/f0f5a7a9a4bb/fimmu-13-952650-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4b2/9530325/02e763ece853/fimmu-13-952650-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4b2/9530325/fc12e75e6680/fimmu-13-952650-g005.jpg

相似文献

1
Potential of conserved antigenic sites in development of universal SARS-like coronavirus vaccines.保守抗原表位在开发通用 SARS 样冠状病毒疫苗中的潜力。
Front Immunol. 2022 Sep 20;13:952650. doi: 10.3389/fimmu.2022.952650. eCollection 2022.
2
Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.三种原型株衍生重组蛋白疫苗对 B.1.1.7、B.1.351 和 B.1.617.1 变异 SARS-CoV-2 诱导产生广谱中和抗体。
Viruses. 2021 Jul 22;13(8):1421. doi: 10.3390/v13081421.
3
Trivalent NDV-HXP-S Vaccine Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in Mice.三价 NDV-HXP-S 疫苗可预防小鼠中亲缘关系较远的 SARS-CoV-2 关切变异株。
Microbiol Spectr. 2022 Jun 29;10(3):e0153822. doi: 10.1128/spectrum.01538-22. Epub 2022 Jun 6.
4
Potential of antibody pair targeting conserved antigenic sites in diagnosis of SARS-CoV-2 variants infection.针对 SARS-CoV-2 变异感染中保守抗原表位的抗体对的潜力。
J Virol Methods. 2022 Nov;309:114597. doi: 10.1016/j.jviromet.2022.114597. Epub 2022 Aug 3.
5
Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants.全面绘制 SARS-CoV-2 RBD 特异性中和抗体的结合热点，用于跟踪免疫逃逸变异株。
Genome Med. 2021 Oct 14;13(1):164. doi: 10.1186/s13073-021-00985-w.
6
Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer.SARS-CoV-2 抗体的结构研究鉴定出一种广谱抗体，通过分解 Spike 三聚体来中和奥密克戎变体。
J Virol. 2022 Aug 24;96(16):e0048022. doi: 10.1128/jvi.00480-22. Epub 2022 Aug 4.
7
Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.全面描述了针对 SARS-CoV-2 刺突蛋白的抗体反应，发现了除轻度感染诱导的表位之外的其他疫苗诱导的表位。
Elife. 2022 Jan 24;11:e73490. doi: 10.7554/eLife.73490.
8
A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.一种糖基化 RBD 蛋白诱导针对奥密克戎和其他变体的增强型中和抗体，提高对 SARS-CoV-2 感染的保护作用。
J Virol. 2022 Sep 14;96(17):e0011822. doi: 10.1128/jvi.00118-22. Epub 2022 Aug 16.
9
Challenges and Prospects in Developing Future SARS-CoV-2 Vaccines: Overcoming Original Antigenic Sin and Inducing Broadly Neutralizing Antibodies.开发未来 SARS-CoV-2 疫苗的挑战与展望：克服原始抗原性和诱导广谱中和抗体。
J Immunol. 2023 Nov 15;211(10):1459-1467. doi: 10.4049/jimmunol.2300315.
10
Neutralizing Monoclonal Antibodies Inhibit SARS-CoV-2 Infection through Blocking Membrane Fusion.中和单克隆抗体通过阻断膜融合抑制 SARS-CoV-2 感染。
Microbiol Spectr. 2022 Apr 27;10(2):e0181421. doi: 10.1128/spectrum.01814-21. Epub 2022 Mar 16.

引用本文的文献

1
Hydrophobin-Fused SARS-CoV-2 RBD production in for COVID-19 serology.用于新冠病毒血清学检测的疏水蛋白融合的新冠病毒受体结合域的生产
Future Sci OA. 2025 Dec;11(1):2527502. doi: 10.1080/20565623.2025.2527502. Epub 2025 Jul 4.
2
The role of cross-reactive immunity to emerging coronaviruses: Implications for novel universal mucosal vaccine design.新兴冠状病毒交叉反应性免疫的作用：对新型通用黏膜疫苗设计的启示。
Saudi Med J. 2023 Oct;44(10):965-972. doi: 10.15537/smj.2023.44.10.20230375.
3
Precise modification of the surface charge of antigen enhances vaccine immunogenicity.

本文引用的文献

1
The challenges of COVID-19 Delta variant: Prevention and vaccine development.新冠病毒德尔塔变异株的挑战：预防与疫苗研发
MedComm (2020). 2021 Oct 19;2(4):846-854. doi: 10.1002/mco2.95. eCollection 2021 Dec.
2
SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）501Y.V2变体的传染性并不更强，但确实存在免疫逃逸。
Cell. 2021 Apr 29;184(9):2362-2371.e9. doi: 10.1016/j.cell.2021.02.042. Epub 2021 Feb 23.
3
Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera.
精确修饰抗原的表面电荷可增强疫苗的免疫原性。
Innovation (Camb). 2023 May 29;4(4):100451. doi: 10.1016/j.xinn.2023.100451. eCollection 2023 Jul 10.
SARS-CoV-2 变体 B.1.351 从自然和疫苗诱导的血清中逃逸的证据。
Cell. 2021 Apr 29;184(9):2348-2361.e6. doi: 10.1016/j.cell.2021.02.037. Epub 2021 Feb 23.
4
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.SARS-CoV-2 变体 B.1.351 和 B.1.1.7 的抗体抗性。
Nature. 2021 May;593(7857):130-135. doi: 10.1038/s41586-021-03398-2. Epub 2021 Mar 8.
5
Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity.循环 Sars-CoV-2 刺突 N439K 变体在保持适应性的同时逃避抗体介导的免疫。
Cell. 2021 Mar 4;184(5):1171-1187.e20. doi: 10.1016/j.cell.2021.01.037. Epub 2021 Jan 28.
6
Rapid Development of SARS-CoV-2 Spike Protein Receptor-Binding Domain Self-Assembled Nanoparticle Vaccine Candidates.SARS-CoV-2 刺突蛋白受体结合域自组装纳米颗粒疫苗候选物的快速开发。
ACS Nano. 2021 Feb 23;15(2):2738-2752. doi: 10.1021/acsnano.0c08379. Epub 2021 Jan 19.
7
D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization.D614G 刺突突变增加了 SARS-CoV-2 对中和作用的敏感性。
Cell Host Microbe. 2021 Jan 13;29(1):23-31.e4. doi: 10.1016/j.chom.2020.11.012. Epub 2020 Dec 1.
8
Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity.抗体对 SARS-CoV-2 功能保守位点的交叉中和作用是由亲和力介导的。
Immunity. 2020 Dec 15;53(6):1272-1280.e5. doi: 10.1016/j.immuni.2020.10.023. Epub 2020 Nov 25.
9
Spike mutation D614G alters SARS-CoV-2 fitness.刺突突变 D614G 改变了 SARS-CoV-2 的适应性。
Nature. 2021 Apr;592(7852):116-121. doi: 10.1038/s41586-020-2895-3. Epub 2020 Oct 26.
10
SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies.SARS-CoV-2 中和抗体结构为治疗策略提供信息。
Nature. 2020 Dec;588(7839):682-687. doi: 10.1038/s41586-020-2852-1. Epub 2020 Oct 12.